LEBANON, NH, USA I February 2, 2016 I ImmuNext announced today that the first patient has been dosed in a Phase 1 clinical trial of the anti-VISTA antibody, JNJ-61610588. JNJ-61610588 is the first anti-VISTA antibody to enter the clinic.
The compound is a monoclonal antibody designed for the treatment of cancer, and was developed as part of the license and collaboration agreement with Janssen Biotech, Inc.. Janssen Research & Development is running the study.
The Phase I trial will enroll patients with advanced solid tumors. The initial portion of the study is designed to evaluate safety, pharmacokinetics, and pharmacodynamics of ascending doses of JNJ-61610588.
Additional information may be found at clinicaltrials.gov, using identifier NCT02671955.
About ImmuNext
ImmuNext discovers and develops immunomodulatory therapeutics for the treatment of cancer and autoimmune diseases.
The anti-VISTA antibody, JNJ-61610588 is our lead product. A great team and a great collaboration allowed JNJ-61610588 to be delivered to the clinic significantly ahead of schedule.
ImmuNext continues to identify and develop a pipeline of novel immunotherapies. For more information visit www.ImmuNext.com.
SOURCE: ImmuNext
Post Views: 62
LEBANON, NH, USA I February 2, 2016 I ImmuNext announced today that the first patient has been dosed in a Phase 1 clinical trial of the anti-VISTA antibody, JNJ-61610588. JNJ-61610588 is the first anti-VISTA antibody to enter the clinic.
The compound is a monoclonal antibody designed for the treatment of cancer, and was developed as part of the license and collaboration agreement with Janssen Biotech, Inc.. Janssen Research & Development is running the study.
The Phase I trial will enroll patients with advanced solid tumors. The initial portion of the study is designed to evaluate safety, pharmacokinetics, and pharmacodynamics of ascending doses of JNJ-61610588.
Additional information may be found at clinicaltrials.gov, using identifier NCT02671955.
About ImmuNext
ImmuNext discovers and develops immunomodulatory therapeutics for the treatment of cancer and autoimmune diseases.
The anti-VISTA antibody, JNJ-61610588 is our lead product. A great team and a great collaboration allowed JNJ-61610588 to be delivered to the clinic significantly ahead of schedule.
ImmuNext continues to identify and develop a pipeline of novel immunotherapies. For more information visit www.ImmuNext.com.
SOURCE: ImmuNext
Post Views: 62
